NCT04257838

Monitoring of Piperacillin-Tazobactam and Meropenem Plasmatic Levels in Critical Patients

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 200 (estimated)
• Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to establish the Piperacillin-Tazobactam and Meropenem Plasmatic Levels to know if it´s necessary to make some adjustment in the recommended dose regimen.

Conditions

• Sepsis
• Septic Shock

Interventions

Type	Name	Description
DRUG	Piperacillin/tazobactam or Meropenem	The plasmatic levels determinations will always be made in state of equilibrium (after the fourth dose) and two samples will be collected: 1. Just before the antibiotic infusion (T0) 2. In the midpoint of time (T50). If the antibiotic is administered every 8 hours this determination will be made at 4 hours. If the antibiotic is administered every 6 hours, the determination will be made at 3 hours. A second complete determination will be made (before the infusion, in the midpoint of time and before the next dose) after the administration of 4 doses as long as a posology modification is made as a consequence of the information received from the plasmatic levels.

Timeline

• Start date: 2020-02-15
• Primary completion: 2020-12-15
• Completion: 2021-03-15
• First posted: 2020-02-06
• Last updated: 2020-02-06

Locations

1 site across 1 country: Spain